Cyrevia (cyclophosphamide high dose) / Accentia - LARVOL DELTA

GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan (YouTube) - "In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan..."

Video

Selective Oral AURKA Inhibitor Treatment for Graft-Versus-Host Disease and Relapse Prophylaxis Following Allogeneic HCT: Single-arm Phase 1 Dose Escalation Trial (HMP Global) - "At the 65th American Society of Hematology (ASH) Annual Meeting, Shernan G Holtan, MD...discusses a phase 1 dose escalation portion of a first-in-human clinical trial of post-transplant cyclophosphamide (PTCy) plus sirolimus and selective oral AURKA inhibitor VIC-1911 for graft-versus-host disease (GVHD) and relapse prophylaxis after myeloablative allogeneic hematopoietic cell transplantation (alloHCT)."

Video

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma #bmtsm #mmsm ⁦ @MyMKaiser

Using a Monoclonal Antibody Plus Chemotherapy in Patients With DLBCL : Episode 7: Treatment Considerations in Primary Refractory vs Early-Relapsed DLBCL - "In the first article of a 2-part series, Joseph M. Tuscano, MD, discusses at a virtual live event with fellow clinicians how to define early-relapsed or primary refractory diffuse large B-cell lymphoma and how this impacts treatments for this patient population."

CAR T-cell Therapy Is the Leading Edge of Care for Post-transplant Lymphoproliferative Disorder (Fred Hutchinson Cancer Research Center) - "'Until recently, the use of CAR T-cell therapy for PTLD had been largely unknown,' says Christopher Blosser, MD...'Aggregated data from our case and the 16 previously published reports show this treatment is safe and effective. CAR T-cell therapy does not appear to cause organ rejection and has limited side effects when compared to other chemotherapies and immunotherapies'....Blosser recommends patients have at least one visit in the clinic. 'More often than not, at least one appointment can help facilitate optimal steps in a patient's care,' he says. 'And the earlier we meet that patient, the more likely we can help improve their outcomes.'"

Media quote

Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting (YouTube) - "Shernan Holtan, MD...briefly discusses the results of a Phase II study evaluating post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil (MMF) for graft-versus-host disease (GvHD) in the myeloablative transplant setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA."

Interview • Video

Updates in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma from ASH 2021 - Episode 7: Triplet or Quadruplet Therapy in Transplant-Ineligible NDMM (OncLive) - "In the context of transplant-ineligible newly diagnosed multiple myeloma, Saad Usmani, MD, considers the role of triplet versus quadruplet therapy....Saad Z. Usmani, MD: In the United States, for transplant-ineligible patients, the 2 regimens that we are utilizing right now are RVd-lite...All of us are familiar with RVd and the RVd-lite regimen, which is a dose attenuated weekly regimen that was developed by doctors...Noopur Raje, [MD,]...They are interesting data, I would probably keep a closer eye on this, but it'll likely not change my practice. I would still continue to utilize either RVd or DRd as part of my standard of care practice."

Video

Prompt Treatment of CAR T-Cell Therapy-Related AEs Can Prevent Long-Term Lasting Effects (Oncology Nursing News) - "'To date, more than 100 patients across the CARTITUDE study program have been dosed with cilta-cel. So when implemented, patient management strategies have reduced the incidence of neurotoxicity, including movement and neurocognitive events,' said Hermann Einsele, MD...while presenting the study findings."

Media quote

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1; N=90; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Feb 2010 ➔ Jan 2018

Trial primary completion date • Biosimilar • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Peripheral T-cell Lymphoma • Triple Negative Breast Cancer

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - P2; N=116; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Nov 2019 ➔ Sep 2019

Trial completion date • Acute Lymphocytic Leukemia • Biosimilar

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: Roswell Park Cancer Institute

New P2 trial • Biosimilar • Endometrial Cancer • Oncology • Ovarian Cancer

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2; N=55; Not yet recruiting; Sponsor: Northwestern University

New P1/2 trial • Biosimilar • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - P1; N=116; Recruiting; Sponsor: National Cancer Institute (NCI); Phase classification: P=N/A ➔ P1

Phase classification • Acute Lymphocytic Leukemia • Biosimilar

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - P2; N=28; Recruiting; Sponsor: University of Washington; Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - P2; N=280; Not yet recruiting; Sponsor: Academic and Community Cancer Research United

New P2 trial • Biosimilar • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Triple Negative Breast Cancer

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - P2; N=454; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Completed ➔ Active, not recruiting; Trial completion date: Aug 2014 ➔ Oct 2018

Enrollment closed • Trial completion date • Biosimilar • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Non-Hodgkin’s Lymphoma • Oncology • Reperfusion Injury • Solid Tumor • Triple Negative Breast Cancer

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - P2; N=30; Recruiting; Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University; Trial primary completion date: Sep 2020 ➔ Apr 2020

Trial primary completion date • Acute Myelogenous Leukemia • Biosimilar • Follicular Lymphoma • Graft versus Host Disease • Multiple Myeloma • Myelodysplastic Syndrome

Crohn's Allogeneic Transplant Study (clinicaltrials.gov) - P2; N=2; Active, not recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Trial primary completion date: Jun 2015 ➔ Feb 2019

Trial primary completion date • Biosimilar • Crohn's disease • Inflammatory Bowel Disease • Oncology • Transplantation

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia (clinicaltrials.gov) - P2; N=145; Suspended; Sponsor: Children's Oncology Group; Recruiting ➔ Suspended

Trial suspension • Biosimilar • Graft versus Host Disease • Hematological Malignancies • Leukemia • Oncology

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease (clinicaltrials.gov) - P0; N=20; Not yet recruiting; Sponsor: Washington University School of Medicine

New trial • Biosimilar • Gene Therapies • Graft versus Host Disease • Hematological Malignancies

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University; N=18 ➔ 0; Initiation date: May 2015 ➔ Nov 2015; Recruiting ➔ Withdrawn; Trial primary completion date: Sep 2020 ➔ Jan 2017

Enrollment change • Trial initiation date • Trial primary completion date • Trial withdrawal • Biosimilar • Cutaneous T-cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (clinicaltrials.gov) - P1/2; N=56; Recruiting; Sponsor: Prescient Therapeutics, Ltd.; Trial primary completion date: Jan 2017 ➔ Jan 2019

Trial primary completion date • Biosimilar • HER2 Breast Cancer • Hormone Receptor Breast Cancer

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2/3; N=63; Completed; Sponsor: National Cancer Institute (NCI); Phase classification: P3 ➔ P2/3

Phase classification • Acute Lymphocytic Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Oncology

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma (clinicaltrials.gov) - P1/2; N=20; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Trial primary completion date: Dec 2016 ➔ Jun 2017

Trial primary completion date • Biosimilar • Mesothelioma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1b; N=42; Not yet recruiting; Sponsor: Fred Hutchinson Cancer Research Center

New P1 trial • Biosimilar • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology